TARS Q1 2023 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+363.8% YoY

Gross Profit

$2M89.8% margin

Operating Income

-$25M-998.1% margin

Net Income

-$23M-936.8% margin

EPS (Diluted)

$-0.88

QoQ Revenue Growth

-75.0%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$211M

Total Liabilities

$38M

Stockholders' Equity

$173M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$539,000	+363.8%
Gross Profit	$2M	$506,000	+343.7%
Operating Income	-$25M	-$20M	-27.8%
Net Income	-$23M	-$20M	-15.7%

Revenue Segments

License And Collaboration

$3M100%